A growing set of downloadable, mix-and-match stem cell resources and activities suitable for a variety of educational settings. All components have been extensively tested, and come with full instructions.
Available in several European languages.
SummaryNumerous clinical trials have attempted to test the benefits of using a patient’s own stem cells (taken from the bone marrow) to treat heart disease. Results have been conflicting; some claim significant improvements in heart function, whilst others report none at all. A group at Imperial College London investigated the possible reasons for this inconsistency and found strange, unexplained discrepancies within reports of many of the clinical trials. They have identified a link between claimed success rates and discrepancies, casting doubts over the validity of this treatment.
- 133 reports of 49 clinical trials were investigated
- 600+ discrepancies were found
- Discrepancies ranged from minor to serious mistakes and misrepresentation of data
- Reports with the most discrepancies claimed most benefit to patients, while those without discrepancies showed no improvement in patients’ conditions
The Centre for Cell Manufacturing Ireland (CCMI) is set to launch today at the Regenerative Medicine Institute (REMEDI), National University of Ireland, Galway. It is the first facility in Ireland to receive a licence from the Irish Medicines Board to manufacture expanded stem cells for human use, and one of only five of its kind in Europe.
The scale of the medical challenges that an ageing population poses for healthcare in the future will require radical solutions; harnessing the potential of stem cells represents a promising strategy. On 12 November members of the public gathered at King’s College London to discuss issues surrounding stem cell research and how their clinical translation may be realised.
